Danaher shows generally healthy financial health, with Full Year 2025 Revenue of $2460B, 300% year-over-year growth, and Q1 2026 Revenue of $600B, a 350% year-over-year increase Earnings remain positive, and Q1 2026 Non-GAAP Adjusted Diluted Net EPS of $206 was up 950% year-over-year Cash generation is a key strength, with Full Year 2025 Operating Cash Flow of $640B, Non-GAAP Free Cash Flow of $530B, and Q1 2026 Non-GAAP Free Cash Flow of $110B Balance sheet liquidity is workable, but Total Debt of $1848B and Net Debt of $1278B at 2026-03-27 make acquisition funding and leverage monitoring important
Financial Health Snapshot
What does Danaher Corporation’s latest financial snapshot show?
Strong. Free cash flow is the strongest factor, with $110B in Q1 2026 and $530B for full year 2025. The main concern is the Masimo acquisition funding and execution.
The latest verified period is Q1 2026, with balance sheet data as of 2026-03-27. This view combines growth, profitability, cash generation, balance-sheet capacity, and capital efficiency. For mission context, see Mission Statement, Vision, & Core Values (2026) of Danaher Corporation (DHR).
Free cash flow deserves deeper analysis first because it best shows how Danaher Corporation can fund growth, absorb acquisition pressure, and manage debt.
Revenue Quality
How durable are Danaher Corporation’s revenue and earnings?
Strong. Recurring revenue and adjusted EPS growth confirm better earnings quality than the modest 050% non-GAAP Core Revenue Growth. The clearest divergence is that reported Q1 2026 revenue rose 350% year over year, but underlying growth was much smaller, so quality looks solid but not broad-based.
Revenue quality is about more than size. Danaher Corporation’s reported growth looks much stronger than its underlying core growth, so investors compare durable revenue with operating income, net income, and EPS across the same periods to see whether sales are turning into real profit and per-share gains.
| Measure | Latest Period | Previous Period | Quality Test | Investor Meaning |
|---|---|---|---|---|
| Revenue | $600B in Q1 2026, up 350% year over year | $2460B for Full Year 2025 | Reported growth is partly unclear versus underlying demand because non-GAAP Core Revenue Growth was 050% | Repeatability looks better than a transactional model, but core growth is still modest |
| Operating Income | $134B at 2026-03-27 | Previous comparable period not supplied | Comparison is unavailable, so leverage cannot be confirmed from the prompt | Investors can see profitability, but not whether it improved faster than revenue |
| Net Income | $103B at 2026-03-27 | Previous comparable period not supplied | Operating, interest, tax, and unusual-item effects are not supplied | Final earnings are positive, but the bridge from sales to bottom line is incomplete |
| Diluted EPS | $145 at 2026-03-27 | Previous comparable period not supplied | Share-count impact cannot be verified from the prompt | Per-share results are positive, but the growth rate versus prior period is not verifiable here |
How durable is Danaher Corporation’s revenue?
The strongest durability signal is the $503B recurring revenue base in Q1 2026, which is larger than the $92000M nonrecurring revenue figure. The biggest visibility limit is that the prompt does not break out verified price, volume, or segment mix effects.
- Demand Quality: Recurring revenue gives better visibility than a purely transactional model, so demand appears more repeatable.
- Pricing and Volume: The prompt gives core growth, but not a verified split between price, volume, and mix.
- Diversification: 5900% of 2025 sales came outside the US, while China exposure was 1100% of 2025 total sales.
That mix makes profitability and cash conversion the next test, and a deeper Mission Statement, Vision, & Core Values (2026) of Danaher Corporation (DHR) review can help connect strategy with earnings quality.
Profitability and Cash Quality
How strong are Danaher Corporation’s profitability and cash flow?
Danaher Corporation’s reported earnings are supported by strong cash generation. The supplied data show solid profitability and $640B full-year 2025 operating cash flow, plus $530B non-GAAP free cash flow and $110B non-GAAP free cash flow in Q1 2026, which confirms cash conversion rather than weak earnings quality.
Danaher Corporation’s gross profit, operating income, and net income all point to positive underlying profitability, while EBITDA of $154B adds another operating view of earnings power. Net income of $103B sits below operating cash flow because cash flow reflects non-cash items and working-capital timing, then free cash flow subtracts capital spending. That matters because free cash flow is what supports dividends, reinvestment, and acquisitions. For broader investor context, see Exploring Danaher Corporation (DHR) Investor Profile: Who's Buying and Why?
| Measure | Latest Period | Previous Period | Verified Driver | Investor Meaning |
|---|---|---|---|---|
| Gross Margin | Unavailable; latest supplied data show gross profit of $359B at 2026-03-27. | Unavailable. | Gross profit is reported, but no verified pricing, mix, volume, or input-cost detail was supplied. | Shows product economics, but margin trend cannot be verified from the supplied data. |
| Operating Margin | Unavailable; latest supplied data show operating income of $134B at 2026-03-27. | Unavailable. | Operating profit is reported, but no verified operating leverage, R&D, SG&A, or restructuring bridge was supplied. | Suggests scale is profitable, but efficiency change cannot be measured here. |
| Net Margin | Unavailable; latest supplied data show net income of $103B at 2026-03-27. | Unavailable. | Net income is reported, but no verified interest, tax, or unusual-item bridge was supplied. | Confirms bottom-line profit, but not the exact margin structure. |
| Operating Cash Flow | $640B full year 2025. | Unavailable. | Cash generation was strong despite reported $6300M interest expense and $20600M income tax expense. | Shows earnings are turning into cash, which supports financial flexibility. |
| Free Cash Flow | $110B Q1 2026 non-GAAP free cash flow. | $530B full year 2025 non-GAAP free cash flow. | Free cash flow remains positive after capital spending; the exact capex amount was not supplied. | Leaves room for reinvestment, dividends, and acquisitions. |
What most affects Danaher Corporation’s cash conversion?
The biggest verified factor is durable free cash flow generation, including 34th consecutive year of free cash flow exceeding net income, which suggests Danaher Corporation’s earnings quality is structurally strong rather than temporary.
- Main Driver: Repeated free cash flow above net income looks structural, not temporary, because it has lasted 34 consecutive years.
- Evidence Gap: The supplied data do not break out working-capital changes or capital expenditure separately.
- Metric to Monitor: Watch operating cash flow growth and non-GAAP free cash flow next period, especially after the reported -3755% and -3786% growth figures.
Balance Sheet Strength
Does Danaher have enough liquidity and debt capacity to support its obligations and investment needs?
Balance sheet and liquidity are Mixed. Danaher has solid cash generation support and refinancing access, but the main concern is $1278B of net debt alongside a large acquisition commitment and heavy goodwill exposure.
Cash alone does not settle the question; Danaher’s position depends on working capital, asset quality, debt service, solvency, liquidity, and refinancing together. The company has meaningful current assets, but it also carries sizable current liabilities, substantial debt, and acquisition-related obligations that can pressure flexibility if operating conditions weaken.
| Area | Latest Evidence | Assessment | Investor Meaning |
|---|---|---|---|
| Cash and Working Capital | Cash And Cash Equivalents of $570B; Total Current Assets of $1394B; Total Current Liabilities of $746B. | Mixed | Near-term obligations appear manageable, but cash and current assets need to keep pace with funding demands. |
| Total and Net Debt | Total Debt of $1848B; Short Term Debt of $92300M; Long Term Debt of $1756B; Net Debt of $1278B. | Mixed | Leverage is meaningful, so debt reduces room for aggressive capital deployment. |
| Debt Service and Refinancing | Euro-denominated senior notes priced on May 05, 2026 show corporate-purpose funding access; quarterly cash dividend of $040 per share paid on April 24, 2026 also uses cash. | Strong | Danaher appears able to access funding and service obligations, even while balancing dividend and deal-related cash needs. |
| Asset Quality | Total Assets of $8354B; Goodwill of $4277B; Intangible Assets of $1717B. | Mixed | Acquisition performance matters because a large share of assets is tied to goodwill and intangibles. |
| Liabilities and Equity | Total Liabilities of $3060B; Total Stockholders Equity of $5295B. | Strong | The equity base is large enough to absorb some shocks, but it does not eliminate leverage and deal risk. |
Which balance-sheet risk matters most for Danaher?
The biggest risk is asset quality, because $4277B of goodwill and $1717B of intangible assets make future acquisition performance the key watch item.
- Current Exposure: Total Current Liabilities are $746B against Cash And Cash Equivalents of $570B.
- Protection: Total Current Assets of $1394B and Total Stockholders Equity of $5295B provide a sizable buffer.
- Warning Signal: Watch whether net debt stays elevated after the Masimo deal, with shareholders approving the transaction on May 04, 2026 and close expected soon subject to final regulatory conditions; the agreement includes Exploring Danaher Corporation (DHR) Investor Profile: Who's Buying and Why?.
Capital Efficiency
Can Danaher Corporation Reinvest Cash Without Weakening Returns?
Capital efficiency looks Strong. Full Year 2025 Operating Cash Flow of $640B, Non-GAAP Free Cash Flow of $530B, and Q1 2026 Non-GAAP Free Cash Flow of $110B suggest internal cash appears sufficient for reinvestment needs and shareholder returns.
Return measures should be read alongside leverage, asset intensity, capital expenditure, working capital, and any external funding needs. For Danaher Corporation, the Danaher Business System matters because it shapes how efficiently cash is converted into growth, while the acquisition profile, including Masimo cash merger, also affects capital discipline. See Danaher Corporation (DHR): History, Ownership, Mission, How It Works & Makes Money.
| Capital Measure | Latest Evidence | Quality Test | Investor Meaning |
|---|---|---|---|
| ROIC | Unavailable; ROIC should be calculated only from complete period-matched financial statements. | Danaher Corporation’s operating discipline and capital efficiency would need to support the result. | Shows whether invested capital is creating operating value if a full model is built later. |
| ROE and ROA | Unavailable; ROE and ROA should be calculated only from complete period-matched financial statements. | Leverage could lift ROE, while asset intensity could restrain ROA. | Helps judge shareholder return quality and asset efficiency without treating leverage as automatic strength. |
| Maintenance and Growth Investment | Research And Development Expenses of $38700M on 2026-03-27; FMP Growth Capital Expenditure of 3612%; examples include Cytiva expanded Xcellerex X-platform bioreactor, SCIEX ZenoTOF 8600, Cepheid Xpert GI Panel, and Leica Biosystems collaboration with AstraZeneca and Daiichi Sankyo. | These signals show reinvestment in bioprocessing, molecular diagnostics, genomic medicines, and Innovation at the Speed of Life, but the maintenance-growth split is not stated. | Suggests meaningful capital is being directed toward future revenue quality and product depth. |
| Internal Funding Capacity | Full Year 2025 Operating Cash Flow of $640B, Non-GAAP Free Cash Flow of $530B, and Q1 2026 Non-GAAP Free Cash Flow of $110B. | Investment appears internally funded, with cash flow available before relying on outside capital. | Supports reinvestment, dividends, and acquisitions with less pressure from dilution or extra leverage. |
Are Danaher Corporation’s returns on capital sustainable?
Mostly yes. The strongest durability source is Danaher Business System discipline plus cash generation, while the main weakening risk is heavier acquisition dependence if integration, especially Masimo cash merger, fails to lift returns.
- Operating Source: Danaher Business System supports margins, process control, and asset efficiency across bioprocessing, diagnostics, and life sciences.
- Funding Requirement: The largest verified capital needs are R&D, growth capital expenditure, and acquisition integration.
- Durability Test: Returns weaken if cash flow falls, leverage rises, or acquisition spending outpaces operating improvement.
Liquidity Buffer
How resilient is Given Company, and which warning signs matter most for Danaher Corporation?
Resilience is Mixed. The main buffer is recurring revenue and strong free cash flow, supported by operations in about 50 countries. The most important verified warning sign is deal execution risk, including $1700M of Masimo transaction-related pretax costs in Q1 2026 and the $990B merger deal before close.
Danaher Corporation’s resilience looks solid enough to handle normal stress, but it is not immunity. Recurring revenue of $503B in Q1 2026, Full Year 2025 Non-GAAP Free Cash Flow of $530B, and Q1 2026 Non-GAAP Free Cash Flow of $110B give it room to fund debt service and investment if conditions soften. The test is whether that cash flow stays steady while acquisition costs, policy pressure, and trade exposure rise. For a deeper structure, Mission Statement, Vision, & Core Values (2026) of Danaher Corporation (DHR) can help connect strategy to resilience.
| Pressure | Financial Effect | Existing Protection | Warning Signal |
|---|---|---|---|
| Revenue or Margin Pressure | Lower operating leverage would reduce earnings, cash flow, and debt capacity if margins soften or revenue slows. | Recurring revenue, global diversification across about 50 countries, and Q1 2026 core revenue in China that increased by a mid-single-digit percentage. | Sustained decline in recurring revenue, margin compression, or weaker cash flow. |
| Working-Capital or Investment Pressure | Receivables, inventory, capex, or acquisition-related costs could absorb cash and reduce financial flexibility. | Non-GAAP free cash flow remained strong in both Full Year 2025 and Q1 2026, which helps internal funding. | Rising operating cash outflow, higher inventory, or weaker free cash flow after close. |
| Interest or Refinancing Pressure | Higher interest burden or refinancing needs would narrow free cash flow and reduce flexibility if funding conditions tighten. | Current cash generation supports funding needs, but leverage details are not provided here. | Higher interest expense, tighter liquidity, or refinancing stress. |
Which financial warning signs should investors monitor at Danaher Corporation?
The two strongest signals are free cash flow after the Masimo close and recurring revenue trends. A third risk is China and trade exposure, but that is a future risk unless adjusted EPS or China sales weaken.
Masimo deal execution and funding pressure
Masimo transaction-related pretax costs of $1700M in Q1 2026 and the $990B merger deal make execution the top watchpoint. The buffer is existing cash generation. Monitor free cash flow after close.
Healthcare policy and reimbursement pressure
Global healthcare reimbursement pressures and shifting healthcare regulations can affect customer budgets and payment timing. The buffer is recurring demand. Monitor recurring revenue for any slowdown that would show customers delaying orders.
China and trade exposure
China was 1100% of 2025 total sales, and China Q1 2026 core revenue increased by a mid-single-digit percentage. The exposure matters because geopolitical trade policies could hit adjusted EPS if demand or sourcing worsens.
Financial Health Scorecard
What does Danaher Corporation’s financial health mean for investors?
Danaher Corporation looks Strong overall, with free cash flow as the strongest factor and acquisition and external policy uncertainty as the weakest. The most important condition for the investment case is whether durable cash generation stays strong enough to preserve flexibility through deal integration and trade pressure.
| Financial Factor | Rating | Evidence and Investor Meaning |
|---|---|---|
| Revenue and Earnings Quality | Strong | Full Year 2025 Revenue of $2460B, 300% year-over-year growth, and Q1 2026 Revenue of $600B with Q1 2026 Non-GAAP Adjusted Diluted Net EPS of $206 show solid growth conversion. |
| Profitability and Cash | Strong | Full Year 2025 Operating Cash Flow of $640B, Non-GAAP Free Cash Flow of $530B, and Q1 2026 Non-GAAP Free Cash Flow of $110B point to strong cash generation. |
| Balance Sheet and Liquidity | Mixed | Cash And Cash Equivalents of $570B supports liquidity, but Total Debt of $1848B and Net Debt of $1278B at 2026-03-27 keep leverage and debt service in focus. |
| Capital Efficiency | Strong | DBS-led operations, R&D, product launches, dividends, and cash-funded M&A suggest disciplined reinvestment and lower dependence on external funding. |
| Financial Resilience | Mixed | Recurring revenue and global reach support stability, but Masimo execution, reimbursement pressure, and trade policy create the main stress points. |
- What Supports the Thesis: Strong free cash flow plus recurring revenue and global reach give Danaher Corporation a durable cash engine.
- What Challenges the Thesis: Acquisition execution, Masimo-related pressure, and policy risk could reduce flexibility if cash needs rise.
- What to Monitor: Recurring revenue, Non-GAAP Free Cash Flow, and Non-GAAP Adjusted Diluted Net EPS.
For readers using Exploring Danaher Corporation (DHR) Investor Profile: Who's Buying and Why?, this scorecard is most useful for scenario work because forecast quality depends on whether cash flow, leverage, and earnings stay aligned.
FAQ
What Do Investors Ask About 's Financial Health?
Investors most often ask about the company's revenue quality, profitability, cash generation, debt, liquidity, capital efficiency, and ability to withstand financial pressure.
How stable is Danaher’s acquisition cash flow?
Danaher’s cash flow appears stable enough to support investor confidence, but acquisition timing matters Full Year 2025 Non-GAAP Free Cash Flow was $530B, and Q1 2026 Non-GAAP Free Cash Flow was $110B Masimo transaction costs and post-close integration should be monitored
How much liquidity supports Danaher’s dividend?
Danaher had Cash And Cash Equivalents of $570B at 2026-03-27 and paid a quarterly cash dividend of $040 per share on April 24, 2026 Dividend support also depends on recurring free cash flow, debt needs, acquisition funding, and ongoing reinvestment
What does recurring sales mean for resilience?
Recurring sales improve resilience because they make revenue more visible and less dependent on one-time purchases Danaher reported Q1 2026 recurring revenue of $503B versus $92000M nonrecurring revenue, giving investors a clearer base for cash flow and earnings monitoring
How might regulation pressure financial flexibility?
Regulation can pressure financial flexibility by slowing approvals, affecting reimbursement, or raising compliance costs Danaher operates in diagnostics, biotechnology, and life sciences markets where healthcare regulations matter Investors should watch recurring revenue, adjusted EPS, and free cash flow for signs of pressure
Are Danaher’s debt levels manageable now?
Danaher’s debt looks manageable but not risk-free At 2026-03-27, Cash And Cash Equivalents were $570B, Total Debt was $1848B, and Net Debt was $1278B The Masimo cash acquisition makes future debt capacity and free cash flow important monitoring points